JPMorgan raised the firm’s price target on Takeda to $14.30 from $13.70 and keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Takeda, Biological E. Limited collaborate to accelerate access to Dengue vaccine
- FDA approvesTakeda’s Eohilia for eosinophilic esophagitis treatment
- Takeda to rapidly initiate the first global Phase 3 trials of TAK-861
- Takeda announces CFO Costa Saroukos to leave, Milano Furuta to succeed
- Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide
